Published 4 issues per year
ISSN Print: 0893-9675
ISSN Online: 2162-6448
Indexed in
Escape from Host-Antitumor Immunity
ABSTRACT
Cancer cells may express proteins recognizable by the individual's immune system as foreign because they are either tumor-specific or not expressed at high levels in normal tissues to which the host is tolerant. There is now much evidence that tumors can be immunogenic, that is, that they frequently express antigens in a form recognizable by the host immune system. This has been shown not only in experimental animals but also for spontaneously occurring human tumors. Tumors therefore may progress by evolving variants that can evade immune responses or by developing other strategies to "escape" the immune response. The purpose of this review is to consider the current status of knowledge concerning these different tumor escape strategies.
-
Cabrera C.M., Jimenez P., Concha A., Garrido F., Ruiz-Cabello F., Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation, Tissue Antigens, 63, 5, 2004. Crossref
-
Spisek Radek, Dhodapkar Madhav V., Immunoprevention of Cancer, Hematology/Oncology Clinics of North America, 20, 3, 2006. Crossref
-
Cabrera Carmen M., López-Nevot Miguel-Ángel, Jiménez Pilar, Garrido Federico, Involvement of the chaperone tapasin in HLA-B44 allelic losses in colorectal tumors, International Journal of Cancer, 113, 4, 2005. Crossref
-
Halapil Eva, Jeddi-Tehrani Mahmood, �sterborg Anders, Mellstedt H�kan, T cell receptor usage in malignant diseases, Springer Seminars in Immunopathology, 21, 1, 1999. Crossref
-
Matzku Siegfried, Z??ller Margot, Specific Immunotherapy of Cancer in Elderly Patients, Drugs & Aging, 18, 9, 2001. Crossref
-
De Vita Ferdinando, Orditura Michele, Galizia Gennaro, Romano Ciro, Infusino Stefania, Auriemma Annunziata, Lieto Eva, Catalano Giuseppe, Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies, Cancer, 86, 10, 1999. Crossref
-
Cabrera C.M., Jiménez P., Cabrera T., Esparza C., Ruiz-Cabello F., Garrido F., Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2 -microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors, Tissue Antigens, 61, 3, 2003. Crossref
-
C�fa� Daniel, Morrison Briggs W., Sckell Axel, Favre Luc, Balli Marietta, Leunig Michael, Gimmi Claude D., Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer, International Journal of Cancer, 83, 3, 1999. Crossref
-
Cochlovius Bj�rn, Linnebacher Michael, Zewe-Welschof Monika, Z�ller Margot, Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell responsein vitro andin vivo, International Journal of Cancer, 83, 4, 1999. Crossref
-
Flechner, Stuart M., Finke, James H., Fairchild, Robert L., Basic Principles of Immunology in Urology, in Campbell-Walsh Urology, 2012. Crossref
-
Straten Per thor, Guldberg Per, Schrama David, Andersen Mads Hald, Moerch Ulrik, Seremet Tina, Siedel Claudia, Reisfeld Ralph A., Becker Jürgen C., In situ cytokine therapy: redistribution of clonally expanded T cells, European Journal of Immunology, 31, 1, 2001. Crossref
-
Méndez Rosa, Ruiz-Cabello Francisco, Rodríguez Teresa, Del Campo Ana, Paschen Annette, Schadendorf Dirk, Garrido Federico, Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy, Cancer Immunology, Immunotherapy, 56, 1, 2007. Crossref
-
Garg Neeraj Kumar, Dwivedi Priya, Prabha Punit, Tyagi Rajeev K., RNA pulsed dendritic cells: An approach for cancer immunotherapy, Vaccine, 31, 8, 2013. Crossref
-
Kortylewski Marcin, Yu Hua, Stat3 as a Potential Target for Cancer Immunotherapy, Journal of Immunotherapy, 30, 2, 2007. Crossref
-
Deepak Praveen, Kumar Sanjay, Kishore Dhiraj, Acharya Arbind, IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma, International Immunology, 22, 1, 2010. Crossref
-
Lineweaver Charles H., Davies Paul C. W., Vincent Mark D., Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model, BioEssays, 36, 9, 2014. Crossref
-
Wondimu Assefa, Zhang Tianqian, Kieber-Emmons Thomas, Gimotty Phyllis, Sproesser Katrin, Somasundaram Rajasekharan, Ferrone Soldano, Tsao Chun-Yen, Herlyn Dorothee, Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice, Cancer Immunology, Immunotherapy, 57, 7, 2008. Crossref
-
Demirtzoglou F.J., Papadopoulos S., Zografos G., Cytolytic and Cytotoxic Activity of a Human Natural Killer Cell Line Genetically Modified to Specifically Recognize HER-2/neu Overexpressing Tumor Cells, Immunopharmacology and Immunotoxicology, 28, 4, 2006. Crossref
-
Bruserud Øystein, Ulvestad Elling, Acute Myelogenous Leukemia Blasts as Accessory Cells during in Vitro T Lymphocyte Activation, Cellular Immunology, 206, 1, 2000. Crossref
-
Halapi Eva, Oligoclonal T cells in human cancer, Medical Oncology, 15, 4, 1998. Crossref
-
Li X, Takahashi Y, Sakamoto K, Nakashima T, Expression of dendritic cell phenotypic antigens in cervical lymph nodes of patients with hypopharyngeal and laryngeal carcinoma, The Journal of Laryngology & Otology, 123, S31, 2009. Crossref
-
Bien Ewa, Balcerska Anna, Adamkiewicz-Drozynska Elzbieta, Rapala Malgorzata, Krawczyk Malgorzata, Stepinski Jan, Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias, Clinical Biochemistry, 42, 10-11, 2009. Crossref
-
Witz Isaac P., Levy-Nissenbaum Orlev, The tumor microenvironment in the post-PAGET era, Cancer Letters, 242, 1, 2006. Crossref
-
Kang Shijun, Yang Chunlan, Luo Rongcheng, Induction of CCL2 by siMAML1 through upregulation of TweakR in melanoma cells, Biochemical and Biophysical Research Communications, 372, 4, 2008. Crossref
-
Zöller Margot, Matzku Siegfried, Cancer Therapy: New Concepts on Active Immunization, Immunobiology, 201, 1, 1999. Crossref
-
Galizia Gennaro, Orditura Michele, Romano Ciro, Lieto Eva, Castellano Paolo, Pelosio Luigi, Imperatore Vincenzo, Catalano Giuseppe, Pignatelli Carlo, De Vita Ferdinando, Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery, Clinical Immunology, 102, 2, 2002. Crossref
-
Zöller Margot, Unexpected Induction of Unresponsiveness by Vaccination With Transformed Salmonella Typhimurium, Journal of Immunotherapy, 25, 2, 2002. Crossref
-
Deepak Praveen, Kumar Sanjay, Acharya Arbind, Overexpression of Interleukin-13 in a Murine T-Cell Lymphoma: A Possible Factor of DL-Induced Immunosuppression and Tumor Progression, Cancer Investigation, 27, 6, 2009. Crossref
-
thor Straten Per, Kirkin Alexei F., Siim Elsebeth, Dahlström Karin, Drzewiecki Krzysztof T., Seremet Tina, Zeuthen Jesper, Becker Jürgen C., Guldberg Per, Tumor Infiltrating Lymphocytes in Melanoma Comprise High Numbers of T-Cell Clonotypes That Are Lost during in Vitro Culture, Clinical Immunology, 96, 2, 2000. Crossref
-
Bhattacharyya Arindam, Mandal Debaprasad, Lahiry Lakshmishri, Sa Gaurisankar, Das Tanya, Black tea protects immunocytes from tumor-induced apoptosis by changing Bcl-2/Bax ratio, Cancer Letters, 209, 2, 2004. Crossref
-
Matar Pablo, Rozados Viviana R, Gervasoni Silvia I, Scharovsky O.Graciela, Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response, International Immunopharmacology, 1, 2, 2001. Crossref
-
Liljefors Maria, Nilsson Bo, Hjelm Skog Anna-Lena, Ragnhammar Peter, Mellstedt Håkan, Frödin Jan-Erik, Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A, International Journal of Cancer, 105, 5, 2003. Crossref
-
De Vita Ferdinando, Orditura Michele, Galizia Gennaro, Romano Ciro, Roscigno Annarita, Lieto Eva, Catalano Giuseppe, Serum Interleukin-10 Levels as a Prognostic Factor in Advanced Non-small Cell Lung Cancer Patients, Chest, 117, 2, 2000. Crossref
-
Sørensen Rikke Bæk, Berge-Hansen Linda, Junker Niels, Hansen Christina Aaen, Hadrup Sine Reker, Schumacher Ton N. M., Svane Inge Marie, Becker Jürgen C., Straten Per thor, Andersen Mads Hald, Unutmaz Derya, The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase, PLoS ONE, 4, 9, 2009. Crossref
-
Zöller Margot, Immunotherapy of Cancer by Active Vaccination: Does Allogeneic Bone Marrow Transplantation after Non-Myeloablative Conditioning Provide a New Option?, Technology in Cancer Research & Treatment, 2, 3, 2003. Crossref
-
Kallfelz Michael, Jung Dirk, Hilmes Christine, Knuth Alexander, Jaeger Elke, Huber Christoph, Seliger Barbara, Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer, International Journal of Cancer, 81, 1, 1999. Crossref
-
Céfai D, Schwaninger R, Balli M, Brunner T, Gimmi C D, Functional characterization of Fas ligand on tumor cells escaping active specific immunotherapy, Cell Death & Differentiation, 8, 7, 2001. Crossref
-
Simonetti O., Goteri G., Lucarini G., Rubini C., Stramazzotti D., Muzio L. Lo, Biagini G., Offidani A., In Melanoma Changes of Immature and Mature Dendritic Cell Expression Correlate with Tumor Thickness: An Immunohistochemical Study, International Journal of Immunopathology and Pharmacology, 20, 2, 2007. Crossref
-
Gritzapis A D, Mamalaki A, Kretsovali A, Papamatheakis J, Belimezi M, Perez S A, Baxevanis C N, Papamichail M, Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells, British Journal of Cancer, 88, 8, 2003. Crossref
-
Yoon Do-Young, Cho Young-Sik, Park Joo-Won, Kim Soo-Hyun, Kim Jong-Wan, Up-regulation of reactive oxygen species (ROS) and resistance to Fas-mediated apoptosis in the C33A cervical cancer cell line transfected with IL-18 receptor, Clinical Chemistry and Laboratory Medicine (CCLM), 42, 5, 2004. Crossref
-
Gilboa Eli, The promise of cancer vaccines, Nature Reviews Cancer, 4, 5, 2004. Crossref
-
Mukherjee Pinku, Ginardi Amelia R., Madsen Cathy S., Sterner Christopher J., Adriance Melissa C., Tevethia Mary J., Gendler Sandra J., Mice with Spontaneous Pancreatic Cancer Naturally Develop MUC-1-Specific CTLs That Eradicate Tumors When Adoptively Transferred, The Journal of Immunology, 165, 6, 2000. Crossref
-
Walden Peter, Interrelationship of Tumour and Immune System, in Function and Regulation of Cellular Systems, 2004. Crossref
-
Saio Masanao, Radoja Sasa, Marino Mike, Frey Alan B., Tumor-Infiltrating Macrophages Induce Apoptosis in Activated CD8+T Cells by a Mechanism Requiring Cell Contact and Mediated by Both the Cell-Associated Form of TNF and Nitric Oxide, The Journal of Immunology, 167, 10, 2001. Crossref
-
Radoja Sasa, Rao T. Dharma, Hillman Deborah, Frey Alan B., Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo, The Journal of Immunology, 164, 5, 2000. Crossref
-
Bell Diana, Chomarat Pascale, Broyles Denise, Netto George, Harb Ghada Moumneh, Lebecque Serge, Valladeau Jenny, Davoust Jean, Palucka Karolina A., Banchereau Jacques, In Breast Carcinoma Tissue, Immature Dendritic Cells Reside within the Tumor, Whereas Mature Dendritic Cells Are Located in Peritumoral Areas, Journal of Experimental Medicine, 190, 10, 1999. Crossref
-
Sleeman J. P., The Lymph Node as a Bridgehead in the Metastatic Dissemination of Tumors, in Lymphatic Metastasis and Sentinel Lymphonodectomy, 157, 2000. Crossref
-
Zbar Andrew P., Tumor Immunobiology, in Immunology for Surgeons, 2002. Crossref
-
Ohm Joyce E., Gabrilovich Dmitry I., Sempowski Gregory D., Kisseleva Ekaterina, Parman Kelly S., Nadaf Sorena, Carbone David P., VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression, Blood, 101, 12, 2003. Crossref
-
Andersen Mads Hald, Becker Jürgen C., Straten Per thor, Regulators of apoptosis: suitable targets for immune therapy of cancer, Nature Reviews Drug Discovery, 4, 5, 2005. Crossref
-
Sredni Benjamin, Weil Merav, Khomenok Gennadi, Lebenthal Ilana, Teitz Seagal, Mardor Yael, Ram Zvi, Orenstein Arie, Kershenovich Amir, Michowiz Shalom, Cohen Yan I., Rappaport Zvi H., Freidkin Ilya, Albeck Michael, Longo Dan L., Kalechman Yona, Ammonium Trichloro(dioxoethylene- o,o ′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop, Cancer Research, 64, 5, 2004. Crossref
-
Hawkins LK, Johnson L, Bauzon M, Nye JA, Castro D, Kitzes GA, Young MD, Holt JK, Trown P, Hermiston TW, Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region, Gene Therapy, 8, 15, 2001. Crossref
-
Chen C, Fang H, Han Z, Ye F, Ji T, Gong D, Li F, Zhou J, Ma D, Gao Q, Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs, Gene Therapy, 21, 11, 2014. Crossref
-
Al-Waili Noori S., Saloom Khelod Y., Al-Waili Thia, Al-Waili Ali, Al-Waili Hamza, Modulation of prostaglandin activity, part 1: Prostaglandin inhibition in the management of nonrheumatologic diseases: Immunologic and hematologic aspects, Advances in Therapy, 24, 1, 2007. Crossref
-
Cui Jiuwei, Li Lingyu, Wang Chang, Jin Haofan, Yao Cheng, Wang Yizhuo, Li Dan, Tian Huimin, Niu Chao, Wang Guanjun, Han Wei, Xu Jianting, Chen Jingtao, Li Wei, Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma, Cytotherapy, 17, 7, 2015. Crossref